

Addressing the Influence of Unmeasured Confounding in Observational Studies with Time-to-Event Outcomes: A Semiparametric Sensitivity Analysis Approach

Linda Amofo¹, Elizabeth Platz², and Daniel Scharfstein¹

¹Department of Population Health Science, University of Utah School of Medicine, Utah,
USA

²Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health,
Maryland, USA

March 6, 2024

Abstract

In this paper, we develop a semiparametric sensitivity analysis approach designed to address unmeasured confounding in observational studies with time-to-event outcomes. We target estimation of the marginal distributions of potential outcomes under competing exposures using influence function-based techniques. We derived the non-parametric influence function for uncensored data and mapped the uncensored data influence function to the observed data influence function. Our methodology is motivated by and applied to an observational study evaluating the effectiveness of radical prostatectomy (RP) versus external beam radiotherapy with androgen deprivation (EBRT+AD) for the treatment of prostate cancer. We also present a simulation study to evaluate the statistical properties of our methodology.

Keywords— Causal Inference, Influence function, Prostate Cancer

1 Introduction

The casual effect of two competing treatments has been formalized as a contrast between the distributions of the potential outcomes (i.e., outcomes under the various treatment options) [Rubin, 2005]. In an experimental setting, treatment assignment is via an external process, and randomization probabilistically ensures that both measured and unmeasured confounders are balanced between treatment groups. Causal effects can then be estimated by simply comparing the distribution of outcomes between the treated and untreated with/without covariate adjustment. In a setting where randomized trials are impractical, observational studies become essential. However, in the observational setting, an internal process determines treatment assignment; for example, existing guidelines may determine a patient’s treatment, or each patient, in consultation with their medical team, decides their own treatment. This internal assignment can lead to systematic differences between treatment groups with respect to measured and unmeasured patient characteristics that are associated with the outcome under investigation. In causal inference, one key, typically untestable, assumption is conditional exchangeability (or no unmeasured confounding), which states

that treatment assignment is statistically independent of the potential outcomes *conditional* on a set of measured covariates. If this assumption holds (along with consistency, positivity, and no interference [Hernán and Robins, 2020]), statistical adjustments can be made to recover the true causal effect of interest. However, what happens if conditional exchangeability fails to hold? It would be useful to have a tool that evaluates the robustness of inferences to deviations from this assumption. In this paper, we develop a sensitivity analysis tool for the observational setting with a time-to-event outcome that is subject to right censoring.

To anchor ideas, consider the observational study conducted by Ennis et al. [2018]. In this study, the authors analyzed the survival outcomes of patients with prostate cancer who underwent one of three treatments: (1) radical prostatectomy (RP), (2) external beam radiotherapy (EBRT) combined with androgen deprivation (AD), or (3) EBRT plus brachytherapy with or without AD. Here, we focus on two of these treatments: RP and EBRT+AD. RP is a surgical procedure, while EBRT+AD is not. In Table 1 of Ennis et al. [2018], they reported pre-treatment characteristics (age, prostate-specific antigen, race/ethnicity, insurance status, income, education, Charlson co-morbidity index, Gleason score, clinical T stage, and year of diagnosis) of the patients by treatment groups. Relative to those treated with EBRT+AD, patients treated with RP were younger, more likely to be white, more likely to have private insurance/managed care, have higher education, have higher income, and have lower Gleason scores. These factors are all associated with better survival and imply that an unadjusted analysis may suggest better survival for RP relative to EBRT+AD *even if* there is no true casual difference. In fact, Ennis et al. [2018]) reported a marked difference between the unadjusted survival curves for RP versus EBRT+AD in favor of better survival with RP. After adjustment for measured factors, the difference was attenuated but remained marked.

Chen [2018] wrote an editorial in response to Ennis et al. [2018] study, saying

“comparisons of widely differing treatments such as radical surgery and RT [radiotherapy] in prostate or any other cancer are particularly difficult to interpret because of known inherent differences in patient characteristics between the treatment groups. As a radiation oncologist, it is not uncommon for me to treat patients who my urologic colleagues feel are not ideal surgical candidates because of existing comorbidities. Although all published studies have attempted to statistically account for some measure of comorbidity burden, existing instruments, such as the Charlson score, are crude and unable to fully account for differences between patients receiving surgical treatment and those receiving RT.”

Chen [2018] argues that there was inadequate control for overall health status, comorbidity burden, and disease characteristics between surgical and RT patients, writing “some urologists may preferentially select patients with relatively low-volume disease or other more favorable characteristics (such as magnetic resonance imaging findings supportive of resectability) for radical prostatectomy, whereas patients who receive RT may more commonly have disease nearer the aggressive end of the high-risk spectrum.” Thus, Chen [2018] believes that there are unmeasured confounding factors that have not been adjusted for when comparing the competing treatments in this observational study. That is, if these factors had been available, they would likely indicate that patients receiving surgery would have less aggressive disease and better health status than patients receiving radiotherapy. This suggests that the adjustment performed based on the measured characteristics in Table 1 of Ennis et al. [2018] may be inadequate, and the reported benefit of RT over EBRT could be too optimistic.

The sensitivity analysis tool developed in this paper will allow us to evaluate the robustness of the findings of Ennis et al. [2018] that are purported to be influenced by unmeasured confounding. The paper is organized as follows. In Section 2, we will present a literature review of methods that have been developed for conducting sensitivity analysis of observational studies with a time-to-event outcome that is subject to right censoring. In Section 3, we will introduce our methodology. In Section 4, we evaluate the robustness of the findings from Ennis et al. [2018]. In Section 5, we present a simulation analysis to show the performance of our method. Section 6 is devoted to discussion.

2 Literature Review

The idea of sensitivity analysis to address concerns about unmeasured confounding in observational studies has a rich history dating back to [Cornfield et al. \[1959\]](#)’s paper in response to [Fisher \[1958\]](#)’s hypothesis about how the apparent association between cigarette smoking and lung cancer could be explained away by the confounding effects of an unmeasured genotype. Over the years, many sensitivity analysis proposals have been developed (see, for example, [Lin et al. \[1998\]](#), [Robins et al. \[2000\]](#), [Brumback et al. \[2004\]](#), [Carnegie et al. \[2016\]](#), [VanderWeele and Ding \[2017\]](#), [Bonvini and Kennedy \[2021\]](#), [Rosenbaum and Rubin \[1983\]](#), [Rosenbaum \[1987, 1988\]](#), [Rosenbaum and Krieger \[1990\]](#), [Rosenbaum \[1991\]](#)). However, relatively little attention has been paid to the setting with a time-to-event outcome.

[Lin et al. \[1998\]](#) developed an approximate bias formula for the effect of a binary treatment in a proportional hazards model due to inadequate adjustment for measured baseline covariates. Their approach assumes (a) the existence of a single unmeasured covariate (binary or normally distributed) that does not interact with the measured covariates, (b) the occurrence of the outcome is rare *or* the effect the unmeasured covariate on the hazard of failure is small, and (c) the unmeasured covariate is conditionally independent of the measured covariates given treatment. They showed that the bias depends on four quantities: (1) the effect of the unmeasured covariate on the hazard of failure among the treated, (2) the effect of the unmeasured covariate on the hazard of failure among the untreated, (3) the mean of the unmeasured covariate among the treated and (4) the mean of the unmeasured covariate among the untreated. These four quantities can be then varied in a sensitivity analysis to recover the effect that would have been observed had the unmeasured covariate been accounted for in the analysis. [Lin et al. \[2013\]](#) generalized the approach of [Lin et al. \[1998\]](#) by providing an approximate bias formula when estimating the effect of measured covariates in a proportional hazards model considering three sources of bias (a) bias due to the omission of a balanced covariate, (b) bias due to data censoring, and (c) bias due to unmeasured confounding. Their approach requires specification of (1) the conditional distribution of the unmeasured confounders given measured covariates and (2) the effect of the unmeasured confounders on the hazard of failure above and beyond measured covariates. While their approach is more general, they only considered applications of a single measured covariate and binary unmeasured confounder.

[Klungsoyr et al. \[2009\]](#) consider drawing inferences about the discrete-time causal marginal hazard ratio in an observational study with a point exposure and measured baseline confounders. To address unmeasured confounding, they introduced a user-specified function that “describes lack of exchangeability between baseline exposed and non-exposed within levels of measured confounders, on a hazard ratio scale”. The further this function differs from one, the greater the deviation from exchangeability (i.e., the greater the influence of unmeasured confounders above and beyond measured confounders). The function is parameterized, and inference about the causal marginal hazard ratio is conducted over a broad range of parameter values. Our proposed approach is similar in spirit to their approach. .

A more recent paper by [Huang et al. \[2020\]](#) focuses on sensitivity analysis for the effect of a binary exposure on competing risk outcomes by adapting the simulated potential confounders approach of [Carnegie et al. \[2016\]](#). The approach of [Huang et al. \[2020\]](#) requires specification of sensitivity parameters that govern (1) the effects of unmeasured confounders on the hazard of the competing outcomes, above and beyond exposure and measured confounders, (2) the effect of unmeasured confounders on exposure above and beyond measured confounders, and (3) the marginal distribution of the unmeasured confounders. They draw inferences on the conditional (on measured and unmeasured confounders) effects of exposure on the hazard of the competing risks using the stochastic and non-stochastic Expectation-Maximization (EM) algorithms over a range of choices for the sensitivity analysis parameters. To reduce complexity, they focus on a single binary confounder whose distribution is assumed to be Bernoulli with probability 0.5.

In a series of papers, Vanderweele and colleagues have developed an approach to evaluate the robustness of findings about treatment effects based on observational data to unmeasured confounding. Their main proposals have been developed in the context of non-survival outcomes, but they argue that they can be used for survival outcomes using approximations. We review relevant papers here.

VanderWeele and Arah [2011] developed a general bias formula that applies to causal mean differences for binary, ordinal and continuous outcomes in a setting with categorical or continuous treatments and categorical or continuous measured and unmeasured confounders. This formula depends on (1) the effect (on a difference in means scale) of the unmeasured confounders on the outcome above and beyond measured confounders and treatment and (2) the difference between conditional distribution of the unmeasured confounders given measured confounders and treatment and the conditional distribution of the unmeasured confounders given measured confounders. The authors also developed a bias formula that applies to the causal risk ratio for a binary outcome. This formula depends on (1) the effect (on a ratio in means scale) on the unmeasured confounders on the outcome above and beyond measured confounders and treatment and (a) the conditional distribution of the unmeasured confounders given measured confounders and treatment. VanderWeele [2013] developed a bias formula for the causal hazard difference (ratio) for a “rare” time-to-event outcome. The formula is similar to the casual risk difference (ratio) except that difference (ratio) in means scale is replaced by difference (ratio) of hazards scale. In order to employ these general bias formulae in practice, considerable simplifying assumptions are required.

Ding and VanderWeele [2016] derived an “assumption-free” lower bound on the conditional (on measured covariates) causal relative risk for a binary outcome - it is the ratio of conditional observed relative risk divided by a conditional “bounding factor”. The conditional bounding factor depends on two conditional quantities: (a) maximum relative risk between treatment and unmeasured confounders and (b) maximum (between treated and untreated) of the maximum relative risks between outcome and unmeasured confounders. In VanderWeele and Ding [2017], they introduced the so-called E-value, which is conditional on measured covariates. The conditional E-value is the largest maximum choice of (a) and (b) such that the conditional causal relative risk must be greater than or equal to one - it is a function of the conditional observed relative risk. If there are reasonable choices of (a) and (b) larger than the conditional E-value, then the conditional causal relative risk can be less than one. In fact, if there exists a stratum of measured confounders such that there are reasonable choices of (a) and (b) larger than the associated conditional E-value, then the marginal causal relative risk can be less than one. Ding and VanderWeele [2016] also derived an “assumption-free” lower bound for the conditional causal risk difference. This bound involves the conditional relative risk bounding factor, the conditional probabilities of the outcome given treatment and conditional probability of treatment. The conditional E-value for the conditional causal risk difference is the same as the conditional E-value for the conditional causal risk ratio. A sufficient, although not necessary condition for the marginal causal risk difference to be greater than zero is that, for each stratum of measured confounders, the choice of (a) and (b) is less than the associated conditional E-value. For time-to-event outcomes, Ding and VanderWeele [2016] consider an *approximate* E-value approach for the conditional casual hazard ratio. Specifically, they replace (b) by the maximum (between treated and untreated) of the maximum hazard ratio between outcome and unmeasured confounders. For “rare” outcomes, they recommend replacing the conditional observed relative risk in the conditional E-value formula with the conditional observed hazard ratio. For “common” outcomes, they recommend replacement by a specified function of the conditional observed hazard ratio.

The methods discussed above target the hazard ratio. In the clinical context (e.g., in patient-centered discussions), the emphasis often shifts to the risks associated with specific treatment options at certain time points. This highlights the need to target the marginal distribution of the potential outcomes under competing exposures. In this paper, we develop an approach that allows one to draw inferences about these distributions over a range of untestable assumptions that quantify deviations from exchangeability using semiparametric efficiency theory.

3 Methods

3.1 Notation

Let X be pre-treatment measured covariates and T be treatment received ($T = 1$ for RP, $T = 0$ for EBRT+AD). Let $Y(t)$ be the time to event under treatment t ($t = 1$ for RP, $t = 0$ for EBRT+AD). We assume that $Y = TY(1) + (1 - T)Y(0)$; these quantities are defined in a world with perfect follow-up. Let $F_t(s) = P[Y(t) \leq s]$ be our target of inference. Let $F_t(s|x) = P[Y \leq s | T = t, X = x]$ and $\pi_t(x) = P[T = t | X = x]$.

Let C be a follow-up time that may preempt observation of Y . We assume there is no follow-up after the occurrence of Y . Let $\tilde{Y} = \min(Y, C)$ be the observed follow-up time and $\Delta = I(Y \leq C)$ indicate observation of the event time of interest. For a random individual, we let the uncensored data be denoted by $O = (X, T, Y)$ and the censored data by $\tilde{O} = (X, T, \tilde{Y}, \Delta)$.

We assume that we observe n i.i.d. copies of \tilde{O} .

3.2 Assumptions

For $t = 0, 1$, we assume

$$\text{logit}\{P[Y(t) \leq s | T = 1 - t, X = x]\} = \text{logit}\{P[Y(t) \leq s | T = t, X = x]\} + \gamma_t, \quad \text{for all } s, \quad (1)$$

where γ_t is a fixed sensitivity analysis parameter that governs deviations from exchangeability. Note that $\gamma_t = 0$ implies that T is independent of $Y(t)$ given X (i.e., exchangeability); this means that, within levels of X , the distribution of $Y(t)$ is the same for those whose observed treatment is $1 - t$ and those whose observed treatment is t . When γ_t is greater (less) than zero, we are assuming that, within levels of X , the distribution of $Y(t)$ is skewed toward shorter (longer) survival times for those whose observed treatment is $1 - t$ relative to those whose observed treatment is t ; the difference increases with the absolute magnitude of γ_t . Our assumption posits that the deviation from exchangeability does not depend on s or the level of X ; while this assumption is not required for our methodology, it greatly simplifies the sensitivity analysis.

We also assume that C is independent of Y given T and X . This implies that

$$\lambda_t^\dagger(u|X) = \lambda_t(u|X), \quad (2)$$

where $\lambda_t^\dagger(u|X) = \lim_{h \rightarrow 0^+} P[u \leq \tilde{Y} < u + h, \Delta = 0 | \tilde{Y} \geq u, T = t, X] / h$ is the treatment/cause-specific (conditional on X) hazard of censoring and $\lambda_t(u|X) = \lim_{h \rightarrow 0^+} P[u \leq C < u + h | C \geq u, T = t, X] / h$ is the net (conditional on X) hazard for censoring. That is, we are assuming that censoring is non-informative, i.e., it is explainable by measured covariates. This assumption also implies that

$$v_t^\dagger(u|X) = v_t(u|X), \quad (3)$$

where $v_t^\dagger(u|X) = \lim_{h \rightarrow 0^+} P[u \leq \tilde{Y} < u + h, \Delta = 1 | \tilde{Y} \geq u, T = t, X] / h$ is the treatment/cause-specific (conditional on X) hazard of failure and $v_t(u|X) = \lim_{h \rightarrow 0^+} P[u \leq Y < u + h | Y \geq u, T = t, X] / h$ is the net (conditional) hazard of failure.

3.3 Identifiability

Under Assumptions (1) and (2), we can express $F_t(s)$ as a functional of the distribution of the observed data as follows:

$$F_t(s) = \int_x \left\{ F_t(s|x) \pi_t(x) + \frac{F_t(s|x) \exp\{\gamma_t\}}{1 - F_t(s|x) + F_t(s|x) \exp\{\gamma_t\}} \pi_{1-t}(x) \right\} dF(x) \quad (4)$$

where

$$F_t(s|x) = 1 - \prod_{u \leq s} \left(1 - d\Upsilon_t^\dagger(u|x)\right),$$

$\Upsilon_t^\dagger(\cdot|x)$ is the cumulative treatment/cause-specific (conditional on $X = x$) hazard of failure and $F(\cdot)$ is the marginal distribution of X . For fixed γ_t , the right hand side of (4) depends on quantities that are identified from the distribution of the observed data.

3.4 Uncensored Data Influence Function

In Appendix A, we derive the uncensored data non-parametric influence function for $F_t(s)$ under Assumption (1):

$$\phi_t(O; F_t(s)) = \underbrace{\phi_{t1}(O) + \phi_{t2}(O) + \phi_{t3}(O)}_{\phi_t(O)} - F_t(s) \quad (5)$$

where

$$\begin{aligned} \phi_{t1}(O) &= I(T = t)I(Y \leq s) \left\{ 1 + \frac{\pi_{1-t}(X)}{\pi_t(X)} \frac{\exp(\gamma_t)}{\{1 - F_t(s|X) + F_t(s|X) \exp(\gamma_t)\}^2} \right\} \\ \phi_{t2}(O) &= -I(T = t) \left\{ \frac{\pi_{1-t}(X)}{\pi_t(X)} \frac{F_t(s|X) \exp(\gamma_t)}{\{1 - F_t(s|X) + F_t(s|X) \exp(\gamma_t)\}^2} \right\} \\ \phi_{t3}(O) &= I(T = 1 - t) \left\{ \frac{F_t(s|X) \exp(\gamma_t)}{1 - F_t(s|X) + F_t(s|X) \exp(\gamma_t)} \right\} \end{aligned}$$

3.5 Observed Data Influence Function

Rotnitzky and Robins [2005] show how to map a full data influence function into an observed data influence function:

$$\begin{aligned} \tilde{\phi}_t(\tilde{O}; F_t(s)) &= \frac{\Delta}{G_T(\tilde{Y}^-|X)} \phi_t(O; F_t(s)) + \frac{(1 - \Delta)}{G_T(\tilde{Y}^-|X)} l_t(\tilde{Y}, T, X; F_t(s)) - \\ &\quad \int_0^{\tilde{Y}} \frac{l_t(u, T, X; F_t(s))}{G_T(u^-|X)} d\Lambda_T^\dagger(u|X) \end{aligned}$$

where $G_t(u|X) = P[C > u|T = t, X] = \prod_{u' \leq u} (1 - d\Lambda_t^\dagger(u'|X))$, $\Lambda_t^\dagger(\cdot|X)$ is the cumulative treatment/cause-specific (conditional on X) hazard of censoring, and $l_t(u, T, X; F_t(s)) = E[\phi_t(O; F_t(s)) | Y \geq u, T, X]$. It can be shown that

$$l_t(u, T, X; F_t(s)) = l_{t1}(u, T, X) + l_{t2}(u, T, X) + l_{t3}(u, T, X) - F_t(s),$$

where

$$\begin{aligned} l_{t1}(u, T, X) &= I(T = t)I(u \leq s) \frac{F_t(s|X) - F_t(u^-|X)}{1 - F_t(u^-|X)} \times \\ &\quad \left\{ 1 + \frac{\pi_{1-t}(X)}{\pi_t(X)} \frac{\exp(\gamma_t)}{\{S_t(s|X) + F_t(s|X) \exp(\gamma_t)\}^2} \right\} \\ l_{t2}(u, T, X) &= \phi_{t2}(O) \\ l_{t3}(u, T, X) &= \phi_{t3}(O) \end{aligned}$$

3.6 Additional Modeling

The observed data influence function depends on $d\Lambda_t^\dagger(\cdot|X)$, $d\Upsilon_t^\dagger(\cdot|X)$ and $\pi_1(X)$ ($\pi_0(X) = 1 - \pi_1(X)$). When X has multiple components, these quantities cannot be estimated at rates fast enough to ensure that an influence function based estimator of $F_t(s)$ will have \sqrt{n} -rates. Thus, we propose to model these quantities using proportional hazards regression. Specifically, we assume

$$d\Lambda_t^\dagger(\cdot|X) = d\Lambda_t^\dagger(\cdot) \exp\{\beta_t' X\} \quad (6)$$

$$d\Upsilon_t^\dagger(\cdot|X) = d\Upsilon_t^\dagger(\cdot) \exp\{\alpha_t'X\}, \quad (7)$$

where $d\Lambda_t^\dagger(\cdot)$ and $d\Upsilon_t^\dagger(\cdot)$ are unspecified treatment/cause-specific baseline hazard functions and β_t and α_t are treatment-specific regression parameters. We posit a generalized additive logistic regression model for $\pi_1(X)$.

3.7 Estimation

In (6) and (7), the regression parameters can be estimated using partial likelihood and the baseline hazards can be estimated using Breslow's estimator. Denote these estimators by $\hat{\beta}_t$, $\hat{\alpha}_t$, $d\hat{\Lambda}_t^\dagger(u)$ and $d\hat{\Upsilon}_t^\dagger(u)$; note that the estimators of the baseline hazards jump at the observed censoring and failure times, respectively. Estimation of the generalized additive logistic regression model for $\pi_1(X)$ uses a back-fitting algorithm. Denote the estimator for $\pi_t(X)$ by $\hat{\pi}_t(X)$.

We can then estimate $F_t(s|X)$ by $\hat{F}_t(s|X) = 1 - \prod_{u \leq s} \left(1 - d\hat{\Upsilon}_t^\dagger(u) \exp\{\hat{\alpha}_t'X\}\right)$ and $G_t(u|X)$ by $\hat{G}_t(u|X) = \prod_{u' \leq u} \left(1 - d\hat{\Lambda}_t^\dagger(u') \exp\{\hat{\beta}_t'X\}\right)$.

This leads to the influence function-based estimator of $F_t(s)$ of

$$\hat{F}_t(s) = \frac{\frac{1}{n} \sum_{i=1}^n \left\{ \frac{\Delta_i}{\hat{G}_{T_i}(\tilde{Y}_i^-|X_i)} \hat{\phi}_t(O) + \frac{(1 - \Delta_i)}{\hat{G}_{T_i}(\tilde{Y}_i^-|X_i)} \hat{l}_t(\tilde{Y}_i, T_i, X_i) - \int_0^{\tilde{Y}_i} \frac{\hat{l}_t(u, T_i, X_i)}{\hat{G}_{T_i}(u^-|X_i)} \exp\{\hat{\beta}_{T_i}'X_i\} d\hat{\Lambda}_{T_i}^\dagger(u) \right\}}{\frac{1}{n} \sum_{i=1}^n \left\{ \frac{1}{\hat{G}_{T_i}(\tilde{Y}_i^-|X_i)} - \int_0^{\tilde{Y}_i} \frac{1}{\hat{G}_{T_i}(u^-|X_i)} \exp\{\hat{\beta}_{T_i}'X_i\} d\hat{\Lambda}_{T_i}^\dagger(u) \right\}},$$

where $\hat{\phi}_t(O) = \hat{\phi}_{t1}(O) + \hat{\phi}_{t2}(O) + \hat{\phi}_{t3}(O)$,

$$\begin{aligned} \hat{\phi}_{t1}(O) &= I(T = t)I(Y \leq s) \left\{ 1 + \frac{\hat{\pi}_{1-t}(X)}{\hat{\pi}_t(X)} \frac{\exp(\gamma_t)}{\{1 - \hat{F}_t(s|X) + \hat{F}_t(s|X) \exp(\gamma_t)\}^2} \right\} \\ \hat{\phi}_{t2}(O) &= -I(T = t) \left\{ \frac{\hat{\pi}_{1-t}(X)}{\hat{\pi}_t(X)} \frac{\hat{F}(s|t, X) \exp(\gamma_t)}{\{1 - \hat{F}_t(s|X) + \hat{F}_t(s|X) \exp(\gamma_t)\}^2} \right\} \\ \hat{\phi}_{t3}(O) &= I(T = 1 - t) \left\{ \frac{\hat{F}(s|t, X) \exp(\gamma_t)}{1 - \hat{F}_t(s|X) + \hat{F}_t(s|X) \exp(\gamma_t)} \right\} \end{aligned}$$

The pool adjacent violators algorithm (PAVA) is used to ensure monotonicity. PAVA works by iteratively adjusting the values of adjacent data points until they are non-decreasing (in the case of increasing curves) or non-increasing (in the case of decreasing curves).

We use the influence function to estimate the variance of $\hat{F}_t(s)$ by

$$\left\{ \frac{1}{n} \sum_{i=1}^n \hat{h}_t(O_i) \right\}^{-2} \left\{ \frac{1}{n^2} \sum_{i=1}^n \left\{ \hat{g}_t(O_i) - \hat{h}(O_i) \hat{F}_t(s) \right\}^2 \right\}$$

4 Data Analysis

We illustrate our proposed method using National Cancer Database (NCDB) data. NCDB is a nationwide comprehensive oncology outcomes database that records $\approx 72\%$ of newly diagnosed cancer cases in the United States annually [ACS, 2024]. Ennis et al. [2018] studied prostate cancer patients who underwent one of three treatments: a surgical procedure radical prostatectomy (RP), treated by one of two therapeutic procedures, external beam radiotherapy (EBRT) combined with androgen deprivation (AD), or EBRT plus brachytherapy with or without AD. In our analysis, we focus on patients with a diagnosis between 2004 and 2010, and similar to the approach taken by Ennis et al. [2018], we include patients with (1) adenocarcinoma of the prostate and with non-metastatic stages (no N+, no M+) and (2) clinical T stage cT3 or higher, biopsy Gleason score ranging from 8 to 10, or PSA ≥ 20

ng/dL. We further excluded low risk patients (i.e., Gleason score ≤ 6 and T-stage = cT1) who at the time of their diagnosis would have been very likely to receive RP. While we increased the comparability of the clinical features of the two treatment groups through this latter restriction, concerns about confounding due to unmeasured factors remain.

We are interested in comparing treatment with RP versus treatment with EBRT + AD with respect to time from treatment initiation until death. Baseline covariates (X) included age, PSA, clinical T stage, Charlson-Deyo score, biopsy Gleason score, insurance status, income (divided into quartiles based on zip code of residence), education (divided into quartiles based on the proportion of residents in the patient’s zip code who did not graduate high school), and race. For our cohort, Table 1 shows the descriptive statistics of covariates overall and by treatment received. Patients who underwent the RP procedure were, on average, seven years younger than those treated with EBRT+AD (62.5 vs. 69.4). There were dramatic differences in type of insurance: a higher percentage of RP patients had private insurance/managed care (56.2% vs. 28.5%), while a greater percentage of EBRT+AD patients had Medicare (60.6% vs. 36.2%).

Our regression models for treatment, censoring, and failure have additive effects of covariates. The generalized additive model for treatment naturally allows for non-linear effects of age and PSA. In the censoring and failure models, we model the effects of these latter covariates using natural cubic splines.

Chen [2018] argue that, within levels of measured covariates, patients who receive RP are likely to be healthier than those receiving EBRT+AD. This implies that γ_1 should be positive and γ_0 should be negative. Figure (1) shows, for each treatment (RP: left panel; EBRT+AD: right panel), estimated survival curves for various sensitivity parameter values: $0.0 \leq \gamma_1 \leq 2$ and $-2.5 \leq \gamma_0 \leq 0.0$. For reference, the figure also presents treatment-specific Kaplan-Meier curves (in red). Notice how the RP (EBRT+AD) Kaplan-Meier curve is an over (under)- estimate of the survival experience had everyone received RP (EBRT+AD).

In Figure 1, the grey curve in the RP (EBRT+AD) panel is an attempt at an under (over)-estimate of survival, thus allowing us to bound the value of the sensitivity analysis parameters. For RP, we include an estimated survival curve for a cohort of higher-risk patients (from the NCDB prostate cancer database) who were diagnosed between 2004 and 2010 and identified with biopsy Gleason scores ranging from 8 to 10 and PSA ≥ 20 ng/dL or T stage \geq cT3. Table 1 shows the descriptive statistics of this higher-risk cohort. The survival of this higher-risk cohort should be worse than if everyone in our main cohort had received RP, i.e., $0 \leq \gamma_1 \leq 1.5$. For EBRT+AD treatment, we include an estimated survival curve for a lower-risk group of patients (from the NCDB prostate cancer database) who were diagnosed between 2004 and 2010 and identified by T stage cT2 or lower (excluding those with T stage \leq cT2a, biopsy Gleason scores ≤ 6 , and PSA levels < 10 ng/dL). NCCN guidelines [Richard et al., 2010] recommend active surveillance as the initial therapy for these patients. Table 1 shows the descriptive statistics of this lower-risk cohort. The survival of this cohort should be better than if everyone in our cohort had received EBRT+AD, i.e., $-2.0 \leq \gamma_0 \leq 0$.

Another way to assess the plausibility of various values of γ_t is to compute induced estimates of the survival curve of $Y(t)$ given $T = 1 - t$ as a function of γ_t (see Figure 2. For fixed γ_t , $P[Y(t) > s|T = 1 - t]$ is equal to $(P[Y(t) > s] - P[Y(t) > s|T = t]P[T = t])/P[T = 1 - t]$, where $P[Y(t) > s|T = t]$ is estimated using the proportional hazards model along with the empirical distribution of X among those who received treatment t , $P[T = t']$ is estimated by the observed proportion of individuals with who received treatment t' and $P[Y(t) > s]$ is estimated using (4). In the left (right) panel of Figure 2, we show the induced survival curves for survival under RP (EBRT+AD) for those who actually took EBRT+AD (RP). For example, the estimated 5-year survival under RP (EBRT+AD) for patients who actually received EBRT+AD (RP) would be 81% (93%) when $\gamma_1 = 1.0$ ($\gamma_0 = -1.0$) versus 93% (86%) when $\gamma_1 = 0$ ($\gamma_0 = 0$). Subject matter experts can use such calculations to judge the plausibility of specific choices of the sensitivity parameters.

Figure 3 displays a contour plot of estimates of the 5-year survival benefit of undergoing RP versus EBRT +

AD for the different combinations of sensitivity parameters γ_1 and γ_0 , respectively. The figure includes the estimate of the 5-year survival benefit of RP over EBRT + AD when $\gamma_1 = \gamma_0 = 0$ (i.e., no unmeasured confounding). This estimate suggests that the 5-year survival benefit of undergoing RP is 7% higher than undergoing EBRT + AD (95% CI: 6% to 8%). The red curve represents the contour along which the 5-year survival benefit is estimated to be zero. We also include the region of sensitivity parameters (bracketed by the blue curves) that would lead to inconclusive results about the relative effect of RP versus EBRT+AD (i.e., 95% confidence interval includes 0). The region to the left (right) of the lower (upper) blue lines indicates combinations of sensitivity analysis parameters that yield evidence in favor of RP (EBRT+AD). These blue curves show the combination of sensitivity parameter values that lead to the same 95% lower and upper confidence interval bounds for the 5-year survival benefit of zero. For reference, we include horizontal and vertical lines at $\gamma_1 = 1.5$ and $\gamma_0 = -2.0$ to indicate the bounds of the sensitivity parameters that we derived from the grey curves depicted in Figure 1. Our analysis suggests that there are values of sensitivity analysis parameters that would suggest that EBRT+AD is more effective than RP. This would happen if, for example, $\gamma_1 = 1.0$ and $\gamma_0 = -1.0$; the plausibility of these values can be judged by reviewing the induced survival curves presented in Figure 2.

5 Simulation Study

5.1 Data Generation

We conducted a simulation study to assess the performance of our method in recovering the true survival curve for a chosen γ_t value. To build a realistic simulation study, we used data from our cohort to build an observed data-generating mechanism. Specifically, we used the empirical distribution of X , the estimated parameters from Weibull regression models for (6) and (7), and the estimated GAM model for treatment as the true observed data generating mechanisms. We considered choices of $\gamma_1 = (0, 1, 2, 3)$ $\gamma_0 = (0, -1, -2, -3)$. For each choice of γ_t along with the true distribution of the observed data, we compute the true survival curve using (4). We considered sample sizes of 1000, 3000, and 5000. For each individual i , we simulated data as follows: (1) randomly sampled covariate vector (X_i) from the original dataset, (2) using X_i , draw treatment assignment (T_i) using the GAM model, (3) using X_i , draw survival time (Y_i) from the Weibull regression model (6) with $t = T_i$ and (4) using X_i , draw censoring time (C_i) from the Weibull regression model (7) with $t = T_i$, and (5) set $\tilde{Y}_i = \min\{Y_i, C_i\}$. For each sample size, we simulated 2000 datasets; for each simulated dataset, we estimated the treatment-specific survival curves using our proposed method. We evaluated estimation bias and 95% confidence interval coverage. We considered two types of confidence intervals: Wald-based and symmetric bootstrap- t [Wilcox, 2017]. We compute confidence intervals on the logit scale and then transform them back to the probability scale. Coverage is measured as the proportion of simulated samples whose 95% confidence intervals contain the truth.

5.2 Results

Figure 4 presents the results of our simulation study; the left (right) panel corresponds to RP (EBRT+AD) and the rows represent sample sizes 1000, 3000 and 5000, respectively. For each γ_t , the solid lines represent the true survival curves and dashed lines represent averages of estimates over the 2000 simulations. The figure shows that when the sensitivity analysis parameter is correctly specified, there is very little bias, regardless of sample size. Table 2, shows bias and 95% confidence interval coverage for different γ_t values at 2, 5, and 10 years. Confidence interval coverage is better for the symmetric bootstrap- t than Wald and gets close to the nominal level with increased sample size, for all values of γ_t .

6 Discussion

In this manuscript, we developed a semiparametric sensitivity analysis approach to address unmeasured confounding in observational studies with time-to-event outcomes subject to right censoring. Our approach allows researchers to quantitatively explore how survival curves and associated treatment effects change under different assumptions about unmeasured confounding.

Our approach assumes that censoring is explainable by measured factors. Like exchangeability, this assumption is untestable. If there is concern that unmeasured factors related to the outcome are associated with censoring, an additional layer of sensitivity analysis can be added (see, for example, [Scharfstein and Robins \[2002\]](#)).

Sensitivity analyses like ours are rarely reported in the scientific literature. Rather, the discussion sections of scientific articles typically mention unmeasured confounding as a potential limitation. This is not surprising as guidelines that provide recommendations on the reporting of results of observational studies do not specifically call for sensitivity analyses. STROBE [[Von Elm et al., 2007](#)] recommends discussing “limitations of the study, taking into account sources of potential bias” and “direction and magnitude of any potential bias”. ROBINS-I [[Sterne et al., 2016a,b](#)] recommends that subject matter experts categorize risk of “bias due to confounding” into one of four categories” “Low risk”, “Moderate risk”, “Serious risk” and “Critical risk”. In making the categorization, the tool asks experts to assess whether “the true effect estimate [can] be predicted to be greater or less than the estimated effect in the study because one or more of the important confounding domains was not controlled for”.

The reporting of such qualitative assessments of bias in the limitations sections of scientific papers would be greatly strengthened by quantitative sensitivity analyses. Subject matter experts could then review the results of the sensitivity analyses to judge the robustness of the study findings to various degrees of unmeasured confounding. This will allow a more reliable and nuanced interpretation of study findings.

R code for implementing the approach considered in this manuscript can be found at <https://github.com/LindaAmofo/SemiparSens>.

References

- ACS. About the national cancer database. <https://www.facs.org/quality-programs/cancer-programs/national-cancer-database/>, 2024. Accessed: 02-05-2024.
- M. Bonvini and E. H. Kennedy. Sensitivity analysis via the proportion of unmeasured confounding. *Journal of the American Statistical Association*, pages 1–11, 2021.
- B. A. Brumback, M. A. Hernán, S. J. Haneuse, and J. M. Robins. Sensitivity analyses for unmeasured confounding assuming a marginal structural model for repeated measures. *Statistics in medicine*, 23(5):749–767, 2004.
- N. B. Carnegie, M. Harada, and J. L. Hill. Assessing sensitivity to unmeasured confounding using a simulated potential confounder. *Journal of Research on Educational Effectiveness*, 9(3):395–420, 2016.
- R. C. Chen. Challenges of interpreting registry data in prostate cancer: interpreting retrospective results along with or in absence of clinical trial data, 2018.
- J. Cornfield, W. Haenszel, E. C. Hammond, A. M. Lilienfeld, M. B. Shimkin, and E. L. Wynder. Smoking and lung cancer: recent evidence and a discussion of some questions. *Journal of the National Cancer institute*, 22(1): 173–203, 1959.
- P. Ding and T. J. VanderWeele. Sensitivity analysis without assumptions. *Epidemiology (Cambridge, Mass.)*, 27(3): 368, 2016.

- R. D. Ennis, L. Hu, S. N. Ryemon, J. Lin, and M. Mazumdar. Brachytherapy-based radiotherapy and radical prostatectomy are associated with similar survival in high-risk localized prostate cancer. *Journal of Clinical Oncology*, 36:1192–1198, 2018.
- R. A. Fisher. Lung cancer and cigarettes? *Nature*, 182(4628):108–108, 1958.
- M. A. Hernán and J. M. Robins. Causal inference, 2020.
- R. Huang, R. Xu, and P. S. Dulai. Sensitivity analysis of treatment effect to unmeasured confounding in observational studies with survival and competing risks outcomes. *Statistics in Medicine*, 39(24):3397–3411, 2020.
- O. Klungsoyr, J. Sexton, I. Sandanger, and J. F. Nygård. Sensitivity analysis for unmeasured confounding in a marginal structural cox proportional hazards model. *Lifetime data analysis*, 15(2):278–294, 2009.
- D. Y. Lin, B. M. Psaty, and R. A. Kronmal. Assessing the sensitivity of regression results to unmeasured confounders in observational studies. *Biometrics*, pages 948–963, 1998.
- N. X. Lin, S. Logan, and W. E. Henley. Bias and sensitivity analysis when estimating treatment effects from the cox model with omitted covariates. *Biometrics*, 69(4):850–860, 2013.
- J. Richard, B. Boston, J. E. Busby, A. D’Amico, J. A. Eastham, C. A. Enke, D. George, R. R. Bahnson, M. Roach III, U. H. D. Family, et al. Nccn®. *Practice Guidelines in Oncology - Prostate Cancer*, 2010.
- J. M. Robins, A. Rotnitzky, and D. O. Scharfstein. Sensitivity analysis for selection bias and unmeasured confounding in missing data and causal inference models. In *Statistical models in epidemiology, the environment, and clinical trials*, pages 1–94. Springer, 2000.
- P. R. Rosenbaum. Sensitivity analysis for certain permutation inferences in matched observational studies. *Biometrika*, 74(1):13–26, 1987.
- P. R. Rosenbaum. Sensitivity analysis for matching with multiple controls. *Biometrika*, 75(3):577–581, 1988.
- P. R. Rosenbaum. Sensitivity analysis for matched case-control studies. *Biometrics*, pages 87–100, 1991.
- P. R. Rosenbaum and A. M. Krieger. Sensitivity of two-sample permutation inferences in observational studies. *Journal of the American Statistical Association*, 85(410):493–498, 1990.
- P. R. Rosenbaum and D. B. Rubin. Assessing sensitivity to an unobserved binary covariate in an observational study with binary outcome. *Journal of the Royal Statistical Society: Series B (Methodological)*, 45(2):212–218, 1983.
- A. Rotnitzky and J. Robins. Inverse probability weighted estimation in survival analysis. *Encyclopedia of Biostatistics*, 4:2619–2625, 2005.
- D. B. Rubin. Causal inference using potential outcomes: Design, modeling, decisions. *Journal of the American Statistical Association*, 100(469):322–331, 2005.
- D. O. Scharfstein and J. M. Robins. Estimation of the failure time distribution in the presence of informative censoring. *Biometrika*, 89(3):617–634, 2002.
- J. A. Sterne, M. A. Hernán, B. C. Reeves, J. Savović, N. D. Berkman, M. Viswanathan, D. Henry, D. G. Altman, M. T. Ansari, I. Boutron, et al. Robins-i: a tool for assessing risk of bias in non-randomised studies of interventions. *bmj*, 355, 2016a.

- J. A. Sterne, J. Higgins, R. Elbers, and B. Reeves. Risk of bias in non-randomized studies of interventions (robins-i): Detailed guidance. <https://www.riskofbias.info/welcome/home/current-version-of-robins-i/robins-i-detailed-guidance-2016>, 2016b. Accessed: 02-13-2024.
- T. J. VanderWeele. Unmeasured confounding and hazard scales: sensitivity analysis for total, direct, and indirect effects. *European journal of epidemiology*, 28(2):113–117, 2013.
- T. J. VanderWeele and O. A. Arah. Bias formulas for sensitivity analysis of unmeasured confounding for general outcomes, treatments, and confounders. *Epidemiology*, pages 42–52, 2011.
- T. J. VanderWeele and P. Ding. Sensitivity analysis in observational research: introducing the e-value. *Annals of internal medicine*, 167(4):268–274, 2017.
- E. Von Elm, D. G. Altman, M. Egger, S. J. Pocock, P. C. Gøtzsche, and J. P. Vandenbroucke. The strengthening the reporting of observational studies in epidemiology (strobe) statement: guidelines for reporting observational studies. *The Lancet*, 370(9596):1453–1457, 2007.
- R. R. Wilcox. *Introduction to robust estimation and hypothesis testing*. Academic press, 2017.

Table 1: Descriptive Statistics for covariates by treatment

Covariates	Our Cohort			Comparable Cohort		
	RP ¹ (N=5005)	EBRT Plus AD ¹ (N=3888)	Overall (N=8893)	Higher Risk ² (N=3433)	Lower Risk ³ (N=41476)	
Age (in years): Mean (SD)	62.5 (7.1)	69.4 (8.5)	65.5 (8.4)	66.9 (9.7)	65.1 (8.5)	
Prostate-Specific Antigen: Mean (SD)	19.6 (21.8)	17.5 (20.0)	22.5 (23.6)	31.6 (27.6)	12.5 (16.2)	
Race						
White	4117 (82.3%)	3040 (78.2%)	7157 (80.5%)	2634 (76.7%)	33346 (80.4%)	
Non-White	888 (17.7%)	848 (21.8%)	1736 (19.5%)	799 (23.3%)	8130 (19.6%)	
Insurance Status						
Private Insurance/Managed Care	2811 (56.2%)	1110 (28.5%)	3921 (44.1%)	1332 (38.8%)	19211 (46.3%)	
Medicare	1814 (36.2%)	2357 (60.6%)	4171 (46.9%)	1693 (49.3%)	18716 (45.1%)	
Other	380 (7.6%)	421 (10.8%)	801 (9%)	408 (11.9%)	3549 (8.6%)	
Income level(\$)						
< 30,000	598 (11.9%)	601 (15.5%)	1199 (13.5%)	529 (15.4%)	5433 (13.1%)	
30,000 – 34,999	808 (16.1%)	689 (17.7%)	1497 (16.8%)	617 (18%)	7011 (16.9%)	
35,000 – 49,999	1326 (26.5%)	1097 (28.2%)	2423 (27.2%)	928 (27%)	11177 (26.9%)	
> 45,000	2273 (45.4%)	1501 (38.6%)	3774 (42.4%)	1359 (39.6%)	17855 (43%)	
Education level⁴						
< 14	742 (14.8%)	705 (18.1%)	1447 (16.3%)	658 (19.2%)	6759 (16.3%)	
14 – 19.99	983 (19.6%)	912 (23.5%)	1895 (21.3%)	769 (22.4%)	9032 (21.8%)	
20 – 28.99	1202 (24%)	948 (24.4%)	2150 (24.2%)	832 (24.2%)	9595 (23.1%)	
> 29	2078 (41.5%)	1323 (34%)	3401 (38.2%)	1174 (34.2%)	16090 (38.8%)	
Charlson Comorbidity Index						
0	4064 (81.2%)	3292 (84.7%)	7356 (82.7%)	2904 (84.6%)	34404 (82.9%)	
≥ 1	941 (18.8%)	596 (15.3%)	1537 (17.3%)	529 (15.4%)	7072 (17.1%)	
Gleason score						
≤ 7	1488 (29.7%)	905 (23.3%)	2393 (26.9%)	1013 (29.5%)	33079 (79.8%)	
8	2273 (45.4%)	1647 (42.4%)	3920 (44.1%)	1235 (36%)	5247 (12.7%)	
≥ 9	1244 (24.9%)	1336 (34.4%)	2580 (29%)	1185 (34.5%)	3150 (7.6%)	
Clinical T stage						
≤ cT2	4238 (84.7%)	3227 (83%)	7465 (83.9%)	1517 (44.2%)	41476 (100%)	
≥ cT3	767 (15.3%)	661 (17%)	1428 (16.1%)	1916 (55.8%)	0 (0%)	

¹ Abbreviations: AD, androgen deprivation; EBRT, external beam radiation; RP, radical prostatectomy.

² Patients classified as higher-risk have biopsy Gleason scores ranging from 8 to 10, and PSA ≥ 20 ng/dL or T stage cT3 or higher.

³ Patients in the lower-risk category are defined by T stage cT2 or lower, excluding those with T stage cT2a or lower, biopsy Gleason scores ≤ 6, and PSA levels < 10 ng/dL.

⁴ Percentiles of adults in the patient's zip code who did not graduate from high school.

Table 2: Simulation Results averaged over simulation replicates. Bias and 95% confidence interval coverage for different γ_t values at 2, 5, and 10 years. For RP, γ_t 's are positive. For EBRT+AD, γ_t 's are negative.

γ_t	Years	Sample Size = 1000						Sample Size = 3000						Sample Size = 5000					
		Bias		95% Wald Confidence Interval Coverage Rate		95% Bootstrap-t Confidence Interval Coverage Rate		Bias		95% Wald Confidence Interval Coverage Rate		95% Bootstrap-t Confidence Interval Coverage Rate		Bias		95% WAlD Confidence Interval Coverage Rate		95% Bootstrap-t Confidence Interval Coverage Rate	
		RP	EBRT + AD	RP	EBRT + AD	RP	EBRT + AD	RP	EBRT + AD	RP	EBRT + AD	RP	EBRT + AD	RP	EBRT + AD	RP	EBRT + AD	RP	EBRT + AD
0	2	0.00	0.00	0.93	0.94	0.97	0.97	0.00	0.00	0.92	0.95	0.95	0.96	0.00	0.00	0.89	0.94	0.93	0.95
	5	0.00	0.00	0.92	0.95	0.94	0.94	0.00	0.00	0.92	0.95	0.93	0.95	0.00	0.00	0.92	0.93	0.94	0.94
	10	0.00	-0.01	0.92	0.94	0.94	0.93	0.00	0.00	0.92	0.94	0.93	0.94	0.00	0.00	0.94	0.94	0.95	0.94
1	2	0.00	0.00	0.89	0.94	0.97	0.96	0.00	0.00	0.89	0.95	0.94	0.95	0.00	0.00	0.86	0.94	0.92	0.94
	5	0.00	0.00	0.92	0.94	0.94	0.94	0.00	0.00	0.92	0.95	0.93	0.96	0.00	0.00	0.92	0.94	0.94	0.94
	10	0.00	0.00	0.91	0.94	0.93	0.93	0.00	0.00	0.92	0.94	0.93	0.94	0.00	0.00	0.94	0.94	0.95	0.94
2	2	0.00	0.00	0.87	0.95	0.97	0.96	0.00	0.00	0.87	0.95	0.94	0.95	0.00	0.00	0.85	0.94	0.92	0.94
	5	0.00	0.00	0.90	0.94	0.94	0.94	0.00	0.00	0.92	0.96	0.94	0.96	0.00	0.00	0.92	0.94	0.94	0.94
	10	0.01	0.00	0.91	0.93	0.93	0.93	0.00	0.00	0.92	0.94	0.93	0.94	0.00	0.00	0.94	0.94	0.95	0.94
3	2	0.01	0.00	0.86	0.95	0.98	0.97	0.00	0.00	0.86	0.95	0.94	0.95	0.00	0.00	0.86	0.94	0.92	0.94
	5	0.01	0.00	0.88	0.94	0.94	0.94	0.00	0.00	0.92	0.96	0.94	0.95	0.00	0.00	0.92	0.94	0.95	0.94
	10	0.01	0.00	0.92	0.94	0.94	0.93	0.00	0.00	0.93	0.95	0.94	0.94	0.00	0.00	0.94	0.94	0.95	0.95




Figure 1: Estimated survival curves for undergoing RP (left panel) and EBRT+AD (right panel) treatments, at specified sensitivity parameter γ_t values.




Figure 2: Induced survival curves for undergoing RP for people who actually underwent EBRT+AD (left panel) and EBRT+AD for people who actually underwent RP (right panel) treatments, at specified values of γ_t .




Figure 3: Contour plot of estimates of the 5-year survival benefit of undergoing RP versus EBRT + AD for the different combinations of sensitivity parameters γ_1 and γ_0 . The blue curves reflect the area of inconclusive results (not favoring either RP or EBRT + AD)




Figure 4: Simulation study results with sample sizes of 1000 (1st row), 3000 (2nd row), and 5000 (3rd row), for RP (1st panel), and EBRT + AD (2nd panel) treatments

Appendix A Uncensored data non-parametric influence function for $F_t(s)$

Under assumption (1),

$$\text{logit}\{P[Y(t) \leq s | T = 1 - t, X = x]\} = \text{logit}\{P[Y(t) \leq s | T = t, X = x]\} + \gamma_t$$

and

$$\begin{aligned} F_t(s) &= \int_x \{P[Y \leq s | T = t, X = x]P[T = t | X = x] + \\ &\quad \frac{P[Y \leq s | T = t, X = x] \exp\{\gamma_t\}}{P[Y > s | T = t, X = x] + P[Y \leq s | T = t, X = x] \exp\{\gamma_t\}} P[T = 1 - t | X = x]\} dF(x) \\ &= \int_x \left\{ F_t(s|x)\pi_t(x) + \frac{F_t(s|x) \exp\{\gamma_t\}}{S_t(s|x) + F_t(s|x) \exp\{\gamma_t\}} \pi_{1-t}(x) \right\} dF(x) \equiv \psi_t(P) \end{aligned}$$

A distribution $\tilde{P} \in \mathcal{M}$ is characterized by $\tilde{F}_t(y | x) = \tilde{P}(Y \leq y | T = t, X = x)$, $\tilde{\pi}_t(x) = \tilde{P}(T = t | X = x)$, and $\tilde{F}(x) = \tilde{P}(X \leq x)$. Let $\{\tilde{P}_\theta : \tilde{P}_\theta \in \mathcal{M}\}$. We consider parametric submodels of the following form:

$$\begin{aligned} d\tilde{F}_\theta(x) &= dF(x)\{1 + \epsilon h(x)\} \\ d\tilde{F}_{t,\theta}(y|x) &= dF_t(y | x)\{1 + \eta_t k_t(y, x)\} \\ \tilde{\pi}_{t,\theta}(x) &= \frac{\{\pi_1(x) \exp\{\delta l(x)\}\}^t \pi_0(x)^{1-t}}{\pi_1(x) \exp\{\delta l(x)\} + \pi_0(x)} \end{aligned}$$

where $\theta = (\epsilon, \eta_0, \eta_1, \delta)$, $\mathbb{E}[h(X)] = 0$, $\mathbb{E}[k_t(Y, X) | T = t, X] = 0$ and $l(X)$ is any function of X . The associated score functions are $h(X)$, $Tk_1(Y, X) + (1 - T)k_0(Y, X)$, and $\{T - \pi_1(X)\}l(X)$.

The target parameter as a function of \tilde{P}_θ , $\psi_t(\tilde{P}_\theta)$, is

$$\begin{aligned} \psi_t(\tilde{P}_\theta) &= \int_x \left\{ \int_y I(y \leq s) d\tilde{F}_{t,\theta}(y | x) \tilde{\pi}_{t,\theta}(x) d\tilde{F}_\theta(x) + \right. \\ &\quad \left. \int_x \frac{\int_y I(y \leq s) \exp(\gamma_t) d\tilde{F}_{t,\theta}(y | x)}{\int_y I(y > s) d\tilde{F}_{t,\theta}(y | x) + \int_y I(y \leq s) d\tilde{F}_{t,\theta}(y | x) \exp(\gamma_t)} \tilde{\pi}_{1-t,\theta}(x) \right\} d\tilde{F}_\theta(x). \end{aligned}$$

The derivative of $\psi_t(\tilde{P}_\theta)$ with respect to ϵ evaluated at $\theta = 0$ is

$$\int_x \left\{ F_t(s|x)\pi_t(x) + \frac{F_t(s|x) \exp(\gamma_t)}{S_t(s|x) + F_t(s|x) \exp(\gamma_t)} \pi_{1-t}(x) \right\} h(x) dF(x).$$

The derivative of $\psi_t(\tilde{P}_\theta)$ with respect to η_t evaluated at $\theta = 0$ is

$$\begin{aligned} &\int_x \int_y I(y \leq s) k_t(y, x) dF_t(y|x) \pi_t(x) dF(x) + \\ &\int_x \int_y \frac{\{I(y \leq s) - F_t(s|x)\} \exp(\gamma_t) \pi_{1-t}(x)}{\{S_t(s|x) + F_t(s|x) \exp(\gamma_t)\}^2 \pi_t(x)} k_t(y, x) dF_t(y|x) \pi_t(x) dF(x) \end{aligned}$$

The derivative of $\psi_t(\tilde{P}_\theta)$ with respect to η_{1-t} evaluated at $\theta = 0$ is 0.

The derivative of $\psi_t(\tilde{P}_\theta)$ with respect to δ evaluated at $\theta = 0$ is

$$\int_x (-1)^{t+1} \left\{ F_t(s|x) - \frac{F_t(s|x) \exp(\gamma_t)}{S_t(s|x) + F_t(s|x) \exp(\gamma_t)} \right\} \pi_1(x) \pi_0(x) l(x) dF(x).$$

Any mean zero observed data random variable can be expressed as

$$\begin{aligned} d(O) &= a(X) + I(T = 1)\{b_1(Y, X) + \pi_0(X)c(X)\} + I(T = 0)\{b_0(Y, X) - \pi_1(X)c(X)\} \\ d(O) &= a(X) + \sum_{t=0}^1 I(T = t)\{b_t(Y, X) + (-1)^{t+1} \pi_{1-t}(X)c(X)\} \end{aligned}$$

where $\mathbb{E}[a(X)] = 0$, $\mathbb{E}[b_t(Y, X)|T = t, X] = 0$ and $c(X)$ is an unspecified function of X . The set of all $d(O)$ is the non-parametric tangent space. To find the non-parametric efficient influence function, we need to find choices of $a(X)$, $b_t(Y, X)$ and $c(X)$ such that $\mathbb{E}[a(X)h(X)] = \partial\psi_t(\tilde{P}_\theta)/\partial\epsilon|_{\theta=0}$, $\mathbb{E}[I(T = t)b_t(Y, X)k_t(Y, X)] = \partial\psi_t(\tilde{P}_\theta)/\partial\eta_t|_{\theta=0}$ and $\mathbb{E}[(T - \pi_1(X))^2 c(X)l(X)] = \psi_t(\tilde{P}_\theta)/\partial\delta|_{\theta=0}$. It can be shown that

$$\begin{aligned} a(X) &= F_t(s|x)\pi_t(x) + \frac{F_t(s|x)\exp(\gamma_t)}{S_t(s|x) + F_t(s|x)\exp(\gamma_t)}\pi_{1-t}(x) - \psi_t(P) \\ b_t(Y, X) &= \{I(Y \leq s) - F_t(s|X)\} \left\{ 1 + \frac{\pi_{1-t}(X)}{\pi_t(X)} \frac{\exp(\gamma_t)}{\{F_t(s|X) + S_t(s|X)\exp(\gamma_t)\}^2} \right\} \\ b_{1-t}(Y, X) &= 0 \\ c(X) &= (-1)^{t+1} \left\{ F_t(s|x) - \frac{F_t(s|x)\exp(\gamma_t)}{S_t(s|x) + F_t(s|x)\exp(\gamma_t)} \right\}. \end{aligned}$$

Hence, the non-parametric efficient influence function that corresponds to ψ_t is as follows:

$$\begin{aligned} \phi_t(O; \psi_t) &= I(T = t) \left\{ I(Y \leq s) + \{I(Y \leq s) - F_t(s|X)\} \left\{ \frac{\pi_{1-t}(X)}{\pi_t(X)} \frac{\exp(\gamma_t)}{\{S_t(s|X) + F_t(s|X)\exp(\gamma_t)\}^2} \right\} \right\} \\ &\quad + I(T = 1 - t) \frac{F_t(s|X)\exp(\gamma_t)}{S_t(s|X) + F_t(s|X)\exp(\gamma_t)} - \psi_t(P) \\ \phi_t(O; \psi_t) &= \phi_t(O) - \psi_t(P) \end{aligned}$$